Likewise, i.t. 7HP349, in combination with anti–CTLA-4, significantly improved median and tumor-free survival compared with anti–CTLA-4 plus vehicle (P < 0.05; Figure 1D). This evidence concerns the gene CTLA4 and neoplasm.